US and UK Sign Tariff-Free Accord on Prescription Drugs.

The UK and US have reached a important commercial pact that will maintain no levies on British medicine exports going into the US market.

Agreement Details of the Pact

In exchange for the tariff guarantee, the UK has committed to raise spending on medicines through the NHS. This move guarantees that duties on these vital exports will stay at zero for a period of three years.

This deal is in response to previous warnings to significantly raise tariffs on patented pharmaceutical products, with potential rates floated up to double the cost.

"This deal with the Britain reinforces the worldwide climate for new treatments and brings long-overdue balance to U.S.–U.K. medicine commerce," a release said.

Commercial Importance

Medicines represent one of the Britain's biggest exports to the US, which is by far the primary destination for large companies like GSK and AstraZeneca.

Statistics indicate that in the year prior to last September, the UK shipped drugs worth billions to the US. This amount accounted for nearly one-fifth of all goods exports in that timeframe.

"This guarantee protects employment, increases capital expenditure and sets the stage for the UK to emerge as a worldwide center for life sciences," a minister commented.

Detailed NHS Changes

The deal entails several specific pledges from the British government:

• Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new treatments to be too expensive by 25%.
• Boosted Medicine Funding: There is a goal to double total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the next decade.
• Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to stay within budget will be capped at 15%. Previously, repayments were more than twenty percent.

Recent Tensions

The deal comes amid a ongoing row between the sector and the UK government over drug pricing and approval rates.

These tensions were exacerbated by arguments that American customers were charged several times more for the equivalent treatments than people in the Britain and the EU.

In recent months, several large drug company projects in the UK have been delayed or abandoned, while major expansions have been pledged toward projects in the United States.

The Science Minister stated that the NHS needed to spend more on medicines, noting that its expenditure on drugs had declined as a proportion of its total funding over the past decade.